Click on image to view larger version.

Figure 1 Relationship between the rate of TVR with bare metal stent implantation and the incremental cost-effectiveness of drug-eluting stent implantation for patients undergoing single-vessel percutaneous coronary intervention. Basic assumptions of the cost-effectiveness model are described in the text. The model projects that drug-eluting stent implantation will be reasonably cost-effective (i.e., cost-effectiveness ratio <$10,000/repeat revascularization avoided) for patients with an expected bare metal stent TVR rate >12% and cost-saving for patients with TVR >20%.